Aakash Desai: Novel approach in colorectal cancer treatment in Nature Portfolio
Aakash Desai, Associate Director of Phase 1 and Precision Oncology Program at UAB O’Neal Comprehensive Cancer Center, shared a post on LinkedIn:
“Novel approach in colorectal cancer treatment in Nature Portfolio
Researchers have developed a protease-cleavable liposome (eLipo anti–PD-L1) that enables co-delivery of anti–PD-L1 antibody and doxorubicin, designed to enhance immune response and tumor targeting in colorectal cancer.
Key Highlights from in vivo studies in mice:
• Tumor-site-specific cleavage by legumain enzyme
• Dual effect: immune activation + chemotherapy
• Improved tumor penetration & immune signaling
• Expression of PD-L1 & legumain confirmed in human CRC tissue
This strategy could offer a more effective approach to overcoming resistance to immune checkpoint inhibitors in CRC, particularly in microsatellite stable tumors that traditionally respond poorly to immunotherapy.
A promising step toward smarter immunochemotherapy!”
Authors: Yixuan Liu, Ying Xie, Yuling Chen, Jialun Duan, Chunjie Bao, Jinling Wang, Hexuan Feng, Mengjie Wang, Yuxin Ren, Peishan Li, Qian Luo, Jiarui Xu, Min Jiang, Yanchen Men, Yang Wu, Jianwei Li, Guiling Wang & Wanliang Lu
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023